カイダ　ケンイチ   KAIDA Kenichi   海田　賢一    所属   埼玉医科大学  医学部 総合医療センター　脳神経内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Corrections: Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial (The Lancet Neurology (2017) 18(1) (35–46) (S1474442217303782) (1
掲載誌名	正式名：The Lancet Neurology ISSNコード：14744422
出版社	Lancet Publishing Group
巻・号・頁	17(1),35-46頁
著者・共著者	Ivo N van Schaik,on behalf of the,Vera Bril,Nan van Geloven,Hans-Peter Hartung,Richard A Lewis,Gen Sobue,John-Philip Lawo,Michaela Praus,Orell Mielke,Billie L Durn,David R Cornblath,Ingemar S J Merkies,A. Sabet,K. George,L. Roberts,R. Carne,S. Blum,R. Henderson,P. Van Damme,J. Demeestere,S. Larue,C. D'Amour,V. Bril,A. Breiner,P. Kunc,M. Valis,J. Sussova,T. Kalous,R. Talab,M. Bednar,T. Toomsoo,I. Rubanovits,K. Gross-Paju,U. Sorro,M. Saarela,M. Auranen,J. Pouget,S. Attarian,G. Le Masson,A. Wielanek-Bachelet,C. Desnuelle,E. Delmont,P. Clavelou,D. Aufauvre,J. Schmidt,J. Zschuentssch,C. Sommer,D. Kramer,O. Hoffmann,C. Goerlitz,J. Haas,M. Chatzopoulos,R. Yoon,R. Gold,P. Berlit,A. Jaspert-Grehl,D. Liebetanz,A. Kutschenko,M. Stangel,C. Trebst,P. Baum,F. Bergh,J. Klehmet,A. Meisel,F. Klostermann,J. Oechtering,H. Lehmann,M. Schroeter,T. Hagenacker,D. Mueller,A. Sperfeld,F. Bethke,V. Drory,A. Algom,D. Yarnitsky,B. Murinson,A. Di Muzio,F. Ciccocioppo,S. Sorbi,S. Mata,A. Schenone,M. Grandis,G. Lauria,D. Cazzato,G. Antonini,S. Morino,D. Cocito,M. Zibetti,T. Yokota,T. Ohkubo,T. Kanda,M. Kawai,K. Kaida,H. Onoue,S. Kuwabara,M. Mori,M. Iijima,K. Ohyama,M. Baba,M. Tomiyama,K. Nishiyama,T. Akutsu,K. Yokoyama,K. Kanai,I. N. van Schaik,F. Eftimov,N. C. Notermans,N. Visser,C. Faber,J. Hoeijmakers,K. Rejdak,U. Chyrchel-Paszkiewicz,C. Casanovas Pons,M. Alberti Aguiló,J. Gamez,M. Figueras,C. Marquez Infante,S. Benitez Rivero,M. Lunn,J. Morrow,D. Gosal,T. Lavin,I. Melamed,A. Testori,S. Ajroud-Driss,D. Menichella,E. Simpson,E. Chi-Ho Lai,M. Dimachkie,R. J. Barohn,S. Beydoun,H. Johl,D. Lange,A. Shtilbans,S. Muley,S. Ladha,M. Freimer,J. Kissel,N. Latov,R. Chin,E. Ubogu,S. Mumfrey,T. Rao,P. MacDonald,K. Sharma,G. Gonzalez,J. Allen,D. Walk,L. Hobson-Webb,K. Gable
発行年月	2018/01
概要	Background Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo. Methods Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan. Adults with definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible. We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks. We did randomisation in a 1:1:1 ratio with an interactive voice and web response system with a block size of six, stratified by region (Japan or non-Japan). The primary outcome was the proportion of patients with a CIDP relapse or who were withdrawn for any other reason during 24 weeks of treatment. Patients, caregivers, and study personnel, including those assess
DOI	10.1016/S1474-4422(17)30378-2
PMID	29122523